Kura Oncology, Inc.

Takeda Pharmaceutical Company Limited

G1 Therapeutics, Inc.

Sumitomo Pharma Switzerland Gmbh

Mirati Therapepeutics, Inc.

Artelo Biosciences, Inc.

Patricia Andres

R Martin Emanuele

Petinka I Vlahova

Mark Andres

Xiaohu Deng

Ekaterina Albert

Dalian Zhao

Zhonghua Zhang

Dipanjan Sengupta

Tsuyoshi Sasaki

Alexander Smith

Emily Marie Rigsbee

Hannah S White

Lei Zhu

Yun Shan

Michael Thomas Brandl

Xufeng Sun

Tabitha Williford

Tanise Shattock-Gordon

Song Chen

Roger Paul Bakale

Ana Rita Neves

Kenneth K Liu

Xiufeng Sun

Craig Michael Bowe

Yue Lu

Catalina Ferrer

Licheng Song

Zhiwei Cao

The present disclosure relates to solid forms of Compound 1, or a pharmaceutically acceptable form thereof, a pharmaceutically acceptable salt of Compound 1, or pharmaceutically acceptable solvate thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.

Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same

Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.

Crystalline forms of a menin inhibitor

This disclosure relates to novel crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea. It also relates to methods of making the disclosed crystalline forms, pharmaceutical compositions and kits comprising them, and methods of treatment and uses comprising their administration.

Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea

This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Morphic forms of G1T38 and methods of manufacture thereof

The present invention relates to malate salt of a multi-tyrosine kinase inhibitor. In particular, the present invention relates to crystalline forms of the malate salt of multi-tyrosine kinase inhibitor N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate (1:1), pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.

Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Growing community of inventors

Bend, OR, United States of America

Patricia Andres